Kazuhisa Sekimizu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazuhisa Sekimizu has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Hiroshi Hamamoto
Department of Infectious Diseases, Faculty of Medicine, Yamagata University, Yamagata, Japan
32 shared publications - Yasuhiko Matsumoto
Meiji Pharmaceutical University: Meiji Yakka Daigaku
15 shared publications Kenichi Ishii
Laboratory of Microbiology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
14 shared publications- Chikara Kaito
Okayama Daigaku
12 shared publications - Takahiro Ito
Division of Cell Fate Dynamics and Therapeutics, Institute for Life and Medical Sciences (LiMe), Kyoto University , Kyoto
8 shared publications Tatsuo Adachi
Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan
6 shared publications
Latest Publications
- 1 January 2017
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 11 (2) , 78-83
Genomic analysis of vancomycin-resistant Staphylococcus aureus VRS3b and its comparison with other VRSA isolates
High-level vancomycin resistance among Staphylococcus aureus poses a grave threat to global health as the treatment options for this pathogen are very limited. A detailed evaluation of the genetic background of vancomycin-resistant S. aureus (VRSA) is expected to facilitate the understanding of its origin and pathogenicity. In this study, we performed the genetic analysis of the clinical VRSA isolates and identified the genetic basis of resistance to multiple antibiotics among these strains, based on the available draft genome sequences. In addition, we generated the draft genome of the strain VRS3b, which was considered to be same as VRS3a based on its isolation from the same patient. We found that strain VRS3b did not harbor the genes responsible for tetracycline and gentamicin, which was further confirmed by the sensitivity towards these antibiotics. Our results suggest that the strains VRS3a and VRS3b are different from the view of antibiotic resistance and highlight the possibility of generation of two distinct VRSA strains from the same patient.
- 1 January 2017
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 11 (2) , 78-83
Genomic analysis of vancomycin-resistant Staphylococcus aureus VRS3b and its comparison with other VRSA isolates
High-level vancomycin resistance among Staphylococcus aureus poses a grave threat to global health as the treatment options for this pathogen are very limited. A detailed evaluation of the genetic background of vancomycin-resistant S. aureus (VRSA) is expected to facilitate the understanding of its origin and pathogenicity. In this study, we performed the genetic analysis of the clinical VRSA isolates and identified the genetic basis of resistance to multiple antibiotics among these strains, based on the available draft genome sequences. In addition, we generated the draft genome of the strain VRS3b, which was considered to be same as VRS3a based on its isolation from the same patient. We found that strain VRS3b did not harbor the genes responsible for tetracycline and gentamicin, which was further confirmed by the sensitivity towards these antibiotics. Our results suggest that the strains VRS3a and VRS3b are different from the view of antibiotic resistance and highlight the possibility of generation of two distinct VRSA strains from the same patient.
- Open Access
- 4 January 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 18543
An Intriguing Correlation Based on the Superimposition of Residue Pairs with Inhibitors that Target Protein-Protein Interfaces
Druggable sites on protein-protein interfaces are difficult to predict. To survey inhibitor-binding sites onto which residues are superimposed at protein-protein interfaces, we analyzed publicly available information for 39 inhibitors that target the protein-protein interfaces of 8 drug targets. By focusing on the differences between residues that were superimposed with inhibitors and non-superimposed residues, we observed clear differences in the distances and changes in the solvent-accessible surface areas (∆SASA). Based on the observation that two or more residues were superimposed onto inhibitors in 37 (95%) of 39 protein-inhibitor complexes, we focused on the two-residue relationships. Application of a cross-validation procedure confirmed a linear negative correlation between the absolute value of the dihedral angle and the sum of the ∆SASAs of the residues. Finally, we applied the regression equation of this correlation to four inhibitors that bind to new sites not bound by the 39 inhibitors as well as additional inhibitors of different targets. Our results shed light on the two-residue correlation between the absolute value of the dihedral angle and the sum of the ∆SASA, which may be a useful relationship for identifying the key two-residues as potential targets of protein-protein interfaces.
- 4 January 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 18543
Open AccessAn Intriguing Correlation Based on the Superimposition of Residue Pairs with Inhibitors that Target Protein-Protein Interfaces
Druggable sites on protein-protein interfaces are difficult to predict. To survey inhibitor-binding sites onto which residues are superimposed at protein-protein interfaces, we analyzed publicly available information for 39 inhibitors that target the protein-protein interfaces of 8 drug targets. By focusing on the differences between residues that were superimposed with inhibitors and non-superimposed residues, we observed clear differences in the distances and changes in the solvent-accessible surface areas (∆SASA). Based on the observation that two or more residues were superimposed onto inhibitors in 37 (95%) of 39 protein-inhibitor complexes, we focused on the two-residue relationships. Application of a cross-validation procedure confirmed a linear negative correlation between the absolute value of the dihedral angle and the sum of the ∆SASAs of the residues. Finally, we applied the regression equation of this correlation to four inhibitors that bind to new sites not bound by the 39 inhibitors as well as additional inhibitors of different targets. Our results shed light on the two-residue correlation between the absolute value of the dihedral angle and the sum of the ∆SASA, which may be a useful relationship for identifying the key two-residues as potential targets of protein-protein interfaces.
- Open Access
- 1 January 2016
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 10 (1) , 9-13
Usefulness of silkworm as a host animal for understanding pathogenicity of Cryptococcus neoformans
We propose Cryptococcus neoformans infection model using silkworm for understanding cryptococcosis and screening of therapeutically effective antibiotics. Silkworm is an insect whose rearing methods were established through a long history of the sericulture industry. Silkworm facilitates experiments using a large number of individuals because of low cost for rearing and few ethical problems caused by killing animals. Silkworm can be reared at 37˚C to perform infection experiments at same temperature to human body. Injection of accurate amounts of samples into hemolymph of silkworm by usual syringes is easy to be done since silkworm has an appropriate size to handle. Moreover two injection methods, injection into hemolymph and intestine, are distinguishable for silkworms. The former is correspondent to intravenous injection, and the latter is to oral administration in humans. Taking these advantages of silkworms as host animals, it is possible to evaluate the virulence factors in C. neoformans and the therapeutic efficacy of antifungal agents.
- 1 January 2016
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 10 (1) , 9-13
Open AccessUsefulness of silkworm as a host animal for understanding pathogenicity of Cryptococcus neoformans
We propose Cryptococcus neoformans infection model using silkworm for understanding cryptococcosis and screening of therapeutically effective antibiotics. Silkworm is an insect whose rearing methods were established through a long history of the sericulture industry. Silkworm facilitates experiments using a large number of individuals because of low cost for rearing and few ethical problems caused by killing animals. Silkworm can be reared at 37˚C to perform infection experiments at same temperature to human body. Injection of accurate amounts of samples into hemolymph of silkworm by usual syringes is easy to be done since silkworm has an appropriate size to handle. Moreover two injection methods, injection into hemolymph and intestine, are distinguishable for silkworms. The former is correspondent to intravenous injection, and the latter is to oral administration in humans. Taking these advantages of silkworms as host animals, it is possible to evaluate the virulence factors in C. neoformans and the therapeutic efficacy of antifungal agents.
- 1 January 2016
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 10 (1) , 24-29
Identification of lysocin E using a silkworm model of bacterial infection
New antimicrobials with novel mechanisms need to be developed to combat antimicrobial-resistant pathogenic bacteria. The current authors recently reported discovery of a new antibiotic named "Lysocin E". Lysocin E was identified using a silkworm model of bacterial infection. The current review discusses the advantages of using a silkworm model of bacterial infection to identify and develop therapeutically efficacious antimicrobials. This review also discusses the discovery of lysocin E and its novel mechanism of action.
- 1 January 2016
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 10 (1) , 24-29
Identification of lysocin E using a silkworm model of bacterial infection
New antimicrobials with novel mechanisms need to be developed to combat antimicrobial-resistant pathogenic bacteria. The current authors recently reported discovery of a new antibiotic named "Lysocin E". Lysocin E was identified using a silkworm model of bacterial infection. The current review discusses the advantages of using a silkworm model of bacterial infection to identify and develop therapeutically efficacious antimicrobials. This review also discusses the discovery of lysocin E and its novel mechanism of action.
- 1 January 2016
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 10 (1) , 40-43
Using silkworms to establish alternative animal models for evaluation of drug-induced tissue injury
Evaluation of tissue injury induced by chemicals is crucial to drug development. Mice and rats, which are effectively used to analyze drug-induced tissue injury, present problems in terms of cost and ethical issues. Although alternative methods have been developed using in vitro techniques or invertebrates, evaluation of ADME and the size of animals are still issues that need to be addressed. Use of silkworms can resolve these problems. Silkworms have pharmacokinetic characteristics similar to those of mammals. Injection of various hepatotoxic chemicals also leads to elevated alanine aminotransferase (ALT) activity in the hemolymph of silkworms. Furthermore, transparent transgenic silkworms expressing GFP have been produced to facilitate continuous analysis without the need to collect hemolymph. Analyses using this silkworm have indicated that the intensity of GFP fluorescence observed on the body surface of the silkworm decreases in a time- and dose-dependent manner when hepatotoxic chemicals are injected. These results suggest that the silkworms can serve as alternative animal model for evaluation of drug-induced tissue injury.
- 1 January 2016
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 10 (1) , 40-43
Using silkworms to establish alternative animal models for evaluation of drug-induced tissue injury
Evaluation of tissue injury induced by chemicals is crucial to drug development. Mice and rats, which are effectively used to analyze drug-induced tissue injury, present problems in terms of cost and ethical issues. Although alternative methods have been developed using in vitro techniques or invertebrates, evaluation of ADME and the size of animals are still issues that need to be addressed. Use of silkworms can resolve these problems. Silkworms have pharmacokinetic characteristics similar to those of mammals. Injection of various hepatotoxic chemicals also leads to elevated alanine aminotransferase (ALT) activity in the hemolymph of silkworms. Furthermore, transparent transgenic silkworms expressing GFP have been produced to facilitate continuous analysis without the need to collect hemolymph. Analyses using this silkworm have indicated that the intensity of GFP fluorescence observed on the body surface of the silkworm decreases in a time- and dose-dependent manner when hepatotoxic chemicals are injected. These results suggest that the silkworms can serve as alternative animal model for evaluation of drug-induced tissue injury.
- Open Access
- 1 January 2016
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 10 (1) , 49-56
Lactic acid bacteria activating innate immunity improve survival in bacterial infection model of silkworm
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2016
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 10 (1) , 49-56
Open AccessLactic acid bacteria activating innate immunity improve survival in bacterial infection model of silkworm
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- Open Access
- 25 November 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 17092
Phenotypic and genomic comparisons of highly vancomycin-resistant Staphylococcus aureus strains developed from multiple clinical MRSA strains by in vitro mutagenesis
The development of vancomycin (VCM) resistance in Staphylococcus aureus threatens global health. Studies of the VCM-resistance mechanism and alternative therapeutic strategies are urgently needed. We mutagenized S. aureus laboratory strains and methicillin-resistant S. aureus (MRSA) with ethyl methanesulfonate and isolated mutants that exhibited high resistance to VCM (minimum inhibitory concentration = 32 μg/ml). These VCM-resistant strains were sensitive to linezolid and rifampicin and partly to arbekacin and daptomycin. Beta-lactams had synergistic effects with VCM against these mutants. VCM-resistant strains exhibited a 2-fold increase in the cell wall thickness. Several genes were commonly mutated among the highly VCM-resistant mutants. These findings suggest that MRSA has a potential to develop high VCM resistance with cell wall thickening by the accumulation of mutations.
- 25 November 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 17092
Open AccessPhenotypic and genomic comparisons of highly vancomycin-resistant Staphylococcus aureus strains developed from multiple clinical MRSA strains by in vitro mutagenesis
The development of vancomycin (VCM) resistance in Staphylococcus aureus threatens global health. Studies of the VCM-resistance mechanism and alternative therapeutic strategies are urgently needed. We mutagenized S. aureus laboratory strains and methicillin-resistant S. aureus (MRSA) with ethyl methanesulfonate and isolated mutants that exhibited high resistance to VCM (minimum inhibitory concentration = 32 μg/ml). These VCM-resistant strains were sensitive to linezolid and rifampicin and partly to arbekacin and daptomycin. Beta-lactams had synergistic effects with VCM against these mutants. VCM-resistant strains exhibited a 2-fold increase in the cell wall thickness. Several genes were commonly mutated among the highly VCM-resistant mutants. These findings suggest that MRSA has a potential to develop high VCM resistance with cell wall thickening by the accumulation of mutations.
- Open Access
- 29 May 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 10722
Diabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes
We previously reported that sugar levels in the silkworm hemolymph, i.e., blood, increase immediately (within 1 h) after intake of a high-glucose diet and that the administration of human insulin decreases elevated hemolymph sugar levels in silkworms. In this hyperglycemic silkworm model, however, administration of pioglitazone or metformin, drugs used clinically for the treatment of type II diabetes, have no effect. Therefore, here we established a silkworm model of type II diabetes for the evaluation of anti-diabetic drugs such as pioglitazone and metformin. Silkworms fed a high-glucose diet over a long time-period (18 h) exhibited a hyperlipidemic phenotype. In these hyperlipidemic silkworms, phosphorylation of JNK, a stress-responsive protein kinase, was enhanced in the fat body, an organ that functionally resembles the mammalian liver and adipose tissue. Fat bodies isolated from hyperlipidemic silkworms exhibited decreased sensitivity to human insulin. The hyperlipidemic silkworms have impaired glucose tolerance, characterized by high fasting hemolymph sugar levels and higher hemolymph sugar levels in a glucose tolerance test. Administration of pioglitazone or metformin improved the glucose tolerance of the hyperlipidemic silkworms. These findings suggest that the hyperlipidemic silkworms are useful for evaluating the hypoglycemic activities of candidate drugs against type II diabetes.
- 29 May 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 10722
Open AccessDiabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes
We previously reported that sugar levels in the silkworm hemolymph, i.e., blood, increase immediately (within 1 h) after intake of a high-glucose diet and that the administration of human insulin decreases elevated hemolymph sugar levels in silkworms. In this hyperglycemic silkworm model, however, administration of pioglitazone or metformin, drugs used clinically for the treatment of type II diabetes, have no effect. Therefore, here we established a silkworm model of type II diabetes for the evaluation of anti-diabetic drugs such as pioglitazone and metformin. Silkworms fed a high-glucose diet over a long time-period (18 h) exhibited a hyperlipidemic phenotype. In these hyperlipidemic silkworms, phosphorylation of JNK, a stress-responsive protein kinase, was enhanced in the fat body, an organ that functionally resembles the mammalian liver and adipose tissue. Fat bodies isolated from hyperlipidemic silkworms exhibited decreased sensitivity to human insulin. The hyperlipidemic silkworms have impaired glucose tolerance, characterized by high fasting hemolymph sugar levels and higher hemolymph sugar levels in a glucose tolerance test. Administration of pioglitazone or metformin improved the glucose tolerance of the hyperlipidemic silkworms. These findings suggest that the hyperlipidemic silkworms are useful for evaluating the hypoglycemic activities of candidate drugs against type II diabetes.
- Open Access
- 22 April 2015
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 68 (10) , 646-648
A novel mutation in the vraS gene of Staphylococcus aureus contributes to reduce susceptibility against daptomycin
- 22 April 2015
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 68 (10) , 646-648
Open AccessA novel mutation in the vraS gene of Staphylococcus aureus contributes to reduce susceptibility against daptomycin
- Open Access
- 1 January 2015
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 9 (2) , 133-135
Current use of silkworm larvae (Bombyx mori) as an animal model in pharmaco-medical research
We advocate the use of silkworm larvae, Bombyx mori, as an animal model for discovery of drug candidates. We have established several disease models using silkworms, which offer technical advantages in drug development and the study of host-pathogen interaction. This mini review briefly describes recent trends in the use of silkworm larvae as a non-mammalian model for drug discovery and it offers suggestions regarding the potential for silkworm use in pharmaceutical-biomedical research.
- 1 January 2015
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 9 (2) , 133-135
Open AccessCurrent use of silkworm larvae (Bombyx mori) as an animal model in pharmaco-medical research
We advocate the use of silkworm larvae, Bombyx mori, as an animal model for discovery of drug candidates. We have established several disease models using silkworms, which offer technical advantages in drug development and the study of host-pathogen interaction. This mini review briefly describes recent trends in the use of silkworm larvae as a non-mammalian model for drug discovery and it offers suggestions regarding the potential for silkworm use in pharmaceutical-biomedical research.